Search
Search Results
-
Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
Apocrine carcinoma is a rare breast cancer subtype. As such, the genomic characteristics of apocrine carcinoma with triple negative...
-
Rare subtypes of triple negative breast cancer: Current understanding and future directions
Rare subtypes of triple-negative breast cancers (TNBC) are a heterogenous group of tumors, comprising 5–10% of all TNBCs. Despite accounting for an...
-
Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer
Breast cancer is a malignant tumor that seriously endangers women’s lives. The prognosis of breast cancer patients differs among molecular types....
-
An exploratory study for tuft cells in the breast and their relevance in triple-negative breast cancer: the possible relationship of SOX9
BackgroundBreast cancer is highly heterogeneous, suggesting that small but relevant subsets have been under-recognized. Rare and mainly...
-
Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma
Atezolizumab (TECENTRIQ®) and nivolumab (OPDIVO®) are both immunotherapeutic indications targeting programmed cell death 1 ligand 1 (PD-L1) and...
-
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
BackgroundCancer/testis antigens (CTAs) participate in the regulation of malignant biological behaviors in breast cancer. However, the function and...
-
Genomics in ‘Personalised’ Management of Breast Carcinoma
Breast cancer is a disease caused by a host of factors which also include accumulation of genetic aberrations over a period of time. Most breast...
-
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer...
-
Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer
BackgroundAberrant expressions of desmoglein 2 (Dsg2) and desmocollin 2(Dsc2), the two most widely distributed desmosomal cadherins, have been found...
-
Triple negative breast cancer: Pitfalls and progress
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or...
-
Heterogeneity of triple negative breast cancer: Current advances in subty** and treatment implications
As the field of translational ‘omics has progressed, refined classifiers at both genomic and proteomic levels have emerged to decipher the...
-
In vitro and in vivo activity of a novel oxamide-hydrazone hybrid derivative against triple-negative breast cancer
Triple-negative breast cancer is a subtype of breast cancer with poor clinical outcome, and currently, no effective targeted therapies are available....
-
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer...
-
DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients
Triple-negative breast cancer is aggressive and metastatic breast cancer type and shows immune evasion, drug resistance, relapse and poor survival....
-
Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer
Triple-negative breast cancer (TNBC) accounts for 15–20% of all invasive breast cancer subtypes. Owing to its clinical characteristics, such as the...
-
Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer
Currently, the survival rate for breast cancer is more than 90%, but once the cancer cells metastasize to distal organs, the survival rate is...
-
Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein
BackgroundThe F11R/JAM-A cell adhesion protein was examined as the therapeutic target in triple negative breast cancer (TNBC) with the use of the...
-
Deep learning-based system for automatic prediction of triple-negative breast cancer from ultrasound images
To develop a deep-learning system for the automatic identification of triple-negative breast cancer (TNBC) solely from ultrasound images. A total of...
-
PFKP deubiquitination and stabilization by USP5 activate aerobic glycolysis to promote triple-negative breast cancer progression
BackgroundTriple-negative breast cancer (TNBC) remains the most challenging subtype of breast cancer and lacks definite treatment targets. Aerobic...
-
Effect of punicalagin on the autophagic cell death in triple-negative breast cancer cells
Triple-negative breast cancer (TNBC) is a highly heterogeneous disease defined by the absence of estrogen receptor (ER), progesterone receptor (PR),...
